- Home
- PFL vs ANGO Comparison
PFL vs ANGO Comparison
Compare PFL & ANGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PFL
- ANGO
- Stock Information
- Founded
- PFL 2003
- ANGO 1988
- Country
- PFL United States
- ANGO United States
- Employees
- PFL N/A
- ANGO N/A
- Industry
- PFL Finance Companies
- ANGO Medical/Dental Instruments
- Sector
- PFL Finance
- ANGO Health Care
- Exchange
- PFL Nasdaq
- ANGO Nasdaq
- Market Cap
- PFL 332.7M
- ANGO 271.1M
- IPO Year
- PFL N/A
- ANGO 2004
- Fundamental
- Price
- PFL $8.30
- ANGO $6.81
- Analyst Decision
- PFL
- ANGO Strong Buy
- Analyst Count
- PFL 0
- ANGO 4
- Target Price
- PFL N/A
- ANGO $12.00
- AVG Volume (30 Days)
- PFL 113.7K
- ANGO 512.7K
- Earning Date
- PFL 01-01-0001
- ANGO 01-03-2025
- Dividend Yield
- PFL 11.53%
- ANGO N/A
- EPS Growth
- PFL N/A
- ANGO N/A
- EPS
- PFL N/A
- ANGO N/A
- Revenue
- PFL N/A
- ANGO $292,726,000.00
- Revenue This Year
- PFL N/A
- ANGO N/A
- Revenue Next Year
- PFL N/A
- ANGO $7.69
- P/E Ratio
- PFL N/A
- ANGO N/A
- Revenue Growth
- PFL N/A
- ANGO N/A
- 52 Week Low
- PFL $6.98
- ANGO $5.26
- 52 Week High
- PFL $8.62
- ANGO $8.25
- Technical
- Relative Strength Index (RSI)
- PFL 30.61
- ANGO 47.01
- Support Level
- PFL $8.16
- ANGO $7.04
- Resistance Level
- PFL $8.60
- ANGO $7.51
- Average True Range (ATR)
- PFL 0.08
- ANGO 0.29
- MACD
- PFL -0.03
- ANGO -0.00
- Stochastic Oscillator
- PFL 31.82
- ANGO 25.53
About PFL PIMCO Income Strategy Fund Shares of Beneficial Interest
PIMCO Income Strategy Fund is a United States-based closed-end management investment company. The fund's investment objective is to seek high current income, consistent with the preservation of capital. It seeks to achieve its objectives by investing in a diversified portfolio of floating and fixed-rate debt instruments.
About ANGO AngioDynamics Inc.
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.